The platelet in diabetes: focus on prevention of ischemic events
about
sameAs
Impact of Modifiable Cardiovascular Risk Factors on Mortality After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of 100 StudiesComparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trialsInterplay between ultrastructural findings and atherothrombotic complications in type 2 diabetes mellitusCoronary artery revascularization in patients with diabetes mellitusThe prothrombotic tendency in metabolic syndrome: focus on the potential mechanisms involved in impaired haemostasis and fibrinolytic balanceConsensus on anti-platelet therapy in peripheral arterial disease: saving lives and limbsUse of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in SpainAir pollution related prothrombotic changes in persons with diabetesRho family Guanine nucleotide exchange factor Brx couples extracellular signals to the glucocorticoid signaling systemState-of-the-Art: Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus.Mean platelet volume in Type 2 diabetes mellitus.Whole blood viscosity assessment issues III: Association with international normalized ratio and thrombocytopeniaCorrelation between albuminuria and spontaneous platelet microaggregate formation in type 2 diabetic patientsEffects of blood pressure and the renin-angiotensin system on platelet activation in type 2 diabetes.Evaluation of mean platelet volume in patients with type 2 diabetes mellitus and blood glucose regulation: a marker for atherosclerosis?PPARgamma gene C161T substitution alters lipid profile in Chinese patients with coronary artery disease and type 2 diabetes mellitus.Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent.Mean platelet volume changes before and after glycated hemoglobin (HbA1c) improvement in a large study population.Activated platelets from diabetic rats cause endothelial dysfunction by decreasing Akt/endothelial NO synthase signaling pathwayA novel small molecule 1,2,3,4,6-penta-O-galloyl-α-D-glucopyranose mimics the antiplatelet actions of insulinInvestigation of mean platelet volume in patients with type 2 diabetes mellitus and in subjects with impaired fasting glucose: a cost-effective tool in primary health care?Mean platelet volume and platelet counts in type 2 diabetes: mellitus on treatment and non-diabetic mellitus controls in Lagos, Nigeria.Coupling factor 6 enhances the spontaneous microaggregation of platelets by decreasing cytosolic cAMP irrespective of antiplatelet therapy.Revascularization for coronary artery disease in diabetes mellitus: angioplasty, stents and coronary artery bypass grafting.Detection of clopidogrel hyporesponsiveness using a point-of-care assay and the impact of additional cilostazol administration after coronary stent implantation in diabetic patients.Cardiovascular disease in diabetes: where does glucose fit in?Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial.Altered platelets' morphological parameters in children with type 1 diabetes – a case-control study.Risk factors for venous thromboembolism after total hip and total knee arthroplasty: a meta-analysis.Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapyAspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials.Increased Benefit With Vorapaxar Use in Patients With a History of Myocardial Infarction and Diabetes Mellitus: What the Data Show Us.High glucose inhibits the aspirin-induced activation of the nitric oxide/cGMP/cGMP-dependent protein kinase pathway and does not affect the aspirin-induced inhibition of thromboxane synthesis in human platelets.Coronary artery disease and diabetes mellitus.Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.Polymorphisms of the PPAR-γ (rs1801282) and Its Coactivator (rs8192673) Have a Minor Effect on Markers of Carotid Atherosclerosis in Patients with Type 2 Diabetes MellitusInterleukin-1-beta and dyslipidemic syndrome as major risk factors for thrombotic complications in type 2 diabetes mellitusHematological indices and their correlation with fasting blood glucose level and anthropometric measurements in type 2 diabetes mellitus patients in Gondar, Northwest Ethiopia.Relationship between Altered Platelet Morphological Parameters and Retinopathy in Patients with Type 2 Diabetes Mellitus.A cardiologist view of vascular disease in diabetes.
P2860
Q26774723-62252B66-62A9-4577-BEE4-D0637F3B0639Q26785723-9E10287E-6FD6-424D-8304-FE87905237E9Q26801308-E6502DF1-DA06-4655-8DC4-6852AA4BA2B2Q26824002-82DD1257-5E78-49AB-8095-C06B9F6774CFQ27003277-CF57A9B3-FD62-457D-A2C4-CA701EF1295AQ28166706-E30FA43C-5F03-4A00-B365-580DC88A0ACBQ28222880-5FCAECBB-1B44-410C-8387-E3C44F1EB0B7Q28393905-958AF8A1-B96A-40F5-8AC0-FF13EAB65166Q28513869-2741A5B1-F136-43EE-8D9A-323FC15D160CQ30373414-7734BB8C-65BA-4556-9192-061F230FDE48Q30420690-7F7DDE06-1781-421E-B4E7-94864736971BQ33401066-73446551-1F17-457F-8015-653183744D9BQ33493041-8308646A-8456-475A-802E-3516D6DB7F48Q33609751-9B4FA104-DCF2-4ED3-8CD9-39717CE33CE9Q33756264-D97D8350-2AF1-4D9D-8C56-0A90EC2AAB0AQ33811239-2E695DEE-4C32-4F55-A045-A9B5F6BEF431Q33873092-505FE486-FF5D-411A-A269-ADDFB5DA16B4Q33904436-965306DB-8BEF-42E3-9A2D-89128516D0CDQ33927945-52520485-C712-4D33-9D94-6EE6879C72FCQ34071537-B99EACBD-10BE-49C1-A487-0F91EE862A06Q34167250-E9ECC7F6-5E6C-4835-A66D-E6104E9C0E29Q34431756-87F19390-B17F-40D0-87CC-806671D69B46Q34579200-41445018-2007-49E2-A686-7073AEB4004FQ34793647-574B86AA-9568-4CF3-AC2C-8AC756885DB9Q35033557-C9DE32B7-6072-4CB5-8A0B-8060D1AAA33FQ35137148-BBDDA73D-2E75-4084-BD98-533F908A9A74Q35195203-74B5E06D-8BAC-4D1D-AD9F-90955EF9BA16Q35345165-1E3E8B0F-77C9-4631-A76F-3305A513CECCQ35597753-FDA5E53B-21CA-4046-94DC-611CC66CC47EQ35755253-67419C00-D514-40A0-B802-3CA62F608EBFQ35991934-89D61AAA-213F-47D8-8682-D5EA0B3F46D2Q36094523-26E2ECA9-C0C2-4A37-8915-FE50FAF296A0Q36339645-E7EF9CE3-F43C-4950-9170-F329B3198A1DQ36355228-EF6DB06F-1169-4792-B78E-AA5454BC7568Q36390892-31685316-BB88-4280-862F-550DE62B9A90Q36582658-156B31A0-DDC2-46CB-AC15-73D06B4F02DCQ36587512-8030C525-1EBB-462E-97BF-33AC6C0E5998Q36710271-8C3E222C-87A1-44B3-9266-726545FDDD62Q36835245-4799025C-6B2C-466A-BE6C-57B470331EEFQ36973815-900D8FE5-17F5-42AC-AEE0-1DBA1C804670
P2860
The platelet in diabetes: focus on prevention of ischemic events
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The platelet in diabetes: focus on prevention of ischemic events
@ast
The platelet in diabetes: focus on prevention of ischemic events
@en
The platelet in diabetes: focus on prevention of ischemic events
@nl
type
label
The platelet in diabetes: focus on prevention of ischemic events
@ast
The platelet in diabetes: focus on prevention of ischemic events
@en
The platelet in diabetes: focus on prevention of ischemic events
@nl
prefLabel
The platelet in diabetes: focus on prevention of ischemic events
@ast
The platelet in diabetes: focus on prevention of ischemic events
@en
The platelet in diabetes: focus on prevention of ischemic events
@nl
P3181
P1433
P1476
The platelet in diabetes: focus on prevention of ischemic events
@en
P2093
John A Colwell
Richard W Nesto
P304
P3181
P356
10.2337/DIACARE.26.7.2181
P407
P577
2003-07-01T00:00:00Z